The Performance of Multi-tracer Multimodality PET in Lymphoma

Peking University Cancer Hospital & Institute200 enrolled

Overview

Investigating the performance of Multi-tracer Multimodality PET in lymphoma

In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by different molecular probe such as FDG, FAPI-04 via multimodality PET (PET/CT and PET/MR). Our Previous studies have shown that uptake of FAPI-04 on PET may be an indicator of lymphoma lesions. The combination of PET with CT/MR allows for depicting metabolic, functional and morphological properties of tumor lesions at the same time, which is therefore an alternative attractive pairing for diagnosis, staging and prognosis of lymphoma.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Positron-Emission Tomography

Eligibility

Sex: ALLMin age: 15 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * pathologically diagnosed as lymphoma; * Written informed consent for receiving FAPI-04 PET examinations. * cancer planned chemotherapy or immunotherapy scheme. * expected survival ≥ 12 weeks Exclusion Criteria: * cannot lie supine for half an hour; * refuse to join the clinical researcher; * severe liver or kidney dysfunction * pregnancy or lactation

Locations (1)

Peking University Cancer Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

SUVmax

Standardized uptake value of 68Ga/ 18F-NOTA-FAPI 04 for target lesion of subject or suspected tumor in each time point window (SUV)

Time frame: 150 days

Central Contacts

Xuejuan Wang, MD

CONTACT

86 010 88196363 xuejuan_wang@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.